Intrahepatic Cholangiocarcinoma: Expert consensus statement

HPB

Volumn 17, Issue 8, 2015, Pages 669-680

  Weber, Sharon M ^a   Ribero, Dario ^b   O'Reilly, Eileen M ^c   Kokudo, Norihiro ^d   Miyazaki, Masaru ^e   Pawlik, Timothy M ^f  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b MAURIZIANO HOSPITAL   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

^e CHIBA UNIVERSITY   (Japan)

^f JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; MITOMYCIN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS; EXTERNAL BEAM RADIOTHERAPY; GALLBLADDER CANCER; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LAPAROSCOPY; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; LONG TERM SURVIVAL; LYMPH NODE DISSECTION; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PROGRESSION FREE SURVIVAL; TUMOR RECURRENCE; VATER PAPILLA CARCINOMA; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DISEASE FREE SURVIVAL; EVIDENCE BASED MEDICINE; LIVER NEOPLASMS; MEDICAL SOCIETY; MORTALITY; PRACTICE GUIDELINE; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CONSENSUS; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SOCIETIES, MEDICAL; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84936990315     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12441     Document Type: Article

References (80)

1. Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, et al,. (2013) Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg 217: 736-750.e4.
2. Maithel SK, Gamblin TC, Kamel I, Corona-Villalobos CP, Thomas M, Pawlik TM,. (2013) Multidisciplinary approaches to intrahepatic cholangiocarcinoma. Cancer 119: 3929-3942.
3. Luo X, Yuan L, Wang Y, Ge R, Sun Y, Wei G,. (2014) Survival outcomes and prognostic factors of surgical therapy for all potentially resectable intrahepatic cholangiocarcinoma: a large single-center cohort study. J Gastrointest Surg 18: 562-572.
4. Gleeson FC, Rajan E, Levy MJ, Clain JE, Topazian MD, Harewood GC, et al,. (2008) EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. Gastrointest Endosc 67: 438-443.
5. Levy MJ, Heimbach JK, Gores GJ,. (2012) Endoscopic ultrasound staging of cholangiocarcinoma. Curr Opin Gastroenterol 28: 244-252.
6. Xu HX, Chen LD, Liu LN, Zhang YF, Guo LH, Liu C,. (2012) Contrast-enhanced ultrasound of intrahepatic cholangiocarcinoma: correlation with pathological examination. Br J Radiol 1016: 1029-1037.
7. Valls C, Guma A, Puig I, Sanchez A, Andia E, Serrano T, et al,. (2000) Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 25: 490-496.
8. Hamrick-Turner J, Abbitt PL, Ros PR,. (1992) Intrahepatic cholangiocarcinoma: MR appearance. AJR Am J Roentgenol 158: 77-79.
9. Murakami T, Nakamura H, Tsuda K, Ishida T, Tomoda K, Hori S, et al,. (1995) Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 5: 165-170.
10. Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD,. (2003) Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 30: 1467-1472.
11. Chong YS, Kim YK, Lee MW, Kim SH, Lee WJ, Rhim HC, et al,. (2012) Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin Radiol 67: 766-773.
12. Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D'Angelica M, Fong Y, et al,. (2008) 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206: 57-65.
13. Edge S, (2009). AJCC Cancer Staging Manual, 7th edn. New York, NY: Springer.
14. Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, et al,. (2011) AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 117: 2170-2177.
15. Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al,. (2009) A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 16: 14-22.
16. Hyder H, Marques H, Pulitano C, Marsh W, Alexandrescu S, Bauer TW, et al,. (2014) A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an East and West experience. JAMA Surg 149: 432-438.
17. Ribero D, Pinna AD, Guglielmi A, Ponti A, Nuzzo G, Giulini SM, et al,. (2012) Surgical approach for long-term survival of patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis of 434 patients. Arch Surg 147: 1107-1113.
18. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al,. (2008) Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248: 84-96.
19. Hyder O, Hatzaras I, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al,. (2013) Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery 153: 811-818.
20. Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K,. (2012) Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg 99: 1711-1717.
21. Farges O, Fuks D, Boleslawski E, Le Treut YP, Castaing D, Laurent A, et al,. (2011) Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009 study group. Ann Surg 254: 824-829; discussion 830.
22. El Rassi ZE, Partensky C, Scoazec JY, Henry L, Lombard-Bohas C, Maddern G,. (1999) Peripheral cholangiocarcinoma: presentation, diagnosis, pathology and management. Eur J Surg Oncol 25: 375-380.
23. Lang H, Sotiropoulos GC, Sgourakis G, Schmitz KJ, Paul A, Hilgard P, et al,. (2009) Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 208: 218-228.
24. Ali SM, Clark CJ, Zaydfudim VM, Que FG, Nagorney DM,. (2013) Role of major vascular resection in patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol 20: 2023-2028.
25. de Jong MC, Nathan H, Sotiropoulos GC, Paul A, Alexandrescu S, Marques H, et al,. (2011) Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 29: 3140-3145.
26. Jonas S, Thelen A, Benckert C, Biskup W, Neumann U, Rudolph B, et al,. (2009) Extended liver resection for intrahepatic cholangiocarcinoma: a comparison of the prognostic accuracy of the fifth and sixth editions of the TNM classification. Ann Surg 249: 303-309.
27. Ercolani G, Vetrone G, Grazi GL, Aramaki O, Cescon M, Ravaioli M, et al,. (2010) Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg 252: 107-114.
28. Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Kato A, Yoshitomi H, et al,. (2009) Significance of repeated resection for recurrent intrahepatic cholangiocarcinoma. Hepatogastroenterology 56: 1-5.
29. Nakagawa T, Kamiyama T, Kurauchi N, Matsushita M, Nakanishi K, Kamachi H, et al,. (2005) Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 29: 728-733.
30. Weber SM, Jarnagin WR, Klimstra D, DeMatteo RP, Fong Y, Blumgart LH,. (2001) Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 193: 384-391.
31. Shimada K, Sano T, Nara S, Esaki M, Sakamoto Y, Kosuge T, et al,. (2009) Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. Surgery 145: 411-416.
32. Choi SB, Kim KS, Choi JY, Park SW, Choi JS, Lee WJ, et al,. (2009) The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 16: 3048-3056.
33. Okami J, Dono K, Sakon M, Tsujie M, Hayashi N, Fujiwara Y, et al,. (2003) Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe. J Gastrointest Surg 7: 850-856.
34. Aoba T, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al,. (2013) Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes. Ann Surg 257: 718-725.
35. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T,. (2008) Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 15: 2787-2794.
36. Goere D, Wagholikar GD, Pessaux P, Carrere N, Sibert A, Vilgrain V, et al,. (2006) Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 20: 721-725.
37. D'Angelica M, Fong Y, Weber S, Gonen M, DeMatteo RP, Conlon K, et al,. (2003) The role of staging laparoscopy in hepatobiliary malignancy: prospective analysis of 401 cases. Ann Surg Oncol 10: 183-189.
38. Allen RA, Lisa JR,. (1949) Combined liver cell and bile duct carcinoma. Am J Pathol 25: 647-655.
39. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L,. (1985) Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer 55: 124-135.
40. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al,. (2003) Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 33: 283-287.
41. Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, et al,. (2012) Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis. Ann Surg Oncol 19: 2869-2876.
42. Liver Cancer Study Group of Japan. (1989) The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg 19: 98-129.
43. Koh KC, Lee H, Choi MS, Lee JH, Paik SW, Yoo BC, et al,. (2005) Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg 189: 120-125.
44. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al,. (2009) Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol 16: 623-629.
45. Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, et al,. (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94: 2040-2046.
46. Wang J, Wang F, Kessinger A,. (2010) Outcome of combined hepatocellular and cholangiocarcinoma of the liver. J Oncol 2010: pii: 917356.
47. Lee JH, Chung GE, Yu SJ, Hwang SY, Kim JS, Kim HY, et al,. (2011) Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol 45: 69-75.
48. Theise ND, Nakashima O, Park YN, Nakanuma Y, (2010). Combined hepatocellular-cholangiocarcinoma. In:, Bosman TF, Carneiro F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System. Lyon: IARC, pp. 225-227.
49. Fowler KJ, Sheybani A, Parker RA III, Doherty S, Brunt EM, Chapman WC, et al,. (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am J Roentgenol 201: 332-339.
50. Portolani N, Baiocchi GL, Coniglio A, Piardi T, Grazioli L, Benetti A, et al,. (2008) Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience. Ann Surg Oncol 15: 1880-1890.
51. Groeschl RT, Turaga KK, Gamblin TC,. (2013) Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma. J Surg Oncol 107: 608-612.
52. El-Serag HB, Engels EA, Landgren O, Chiao E, Henderson L, Amaratunge HC, et al,. (2009) Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of US veterans. Hepatology 49: 116-123.
53. Hammill CW, Wong LL,. (2008) Intrahepatic cholangiocarcinoma: a malignancy of increasing importance. J Am Coll Surg 207: 594-603.
54. Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD,. (2007) Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11: 1488-1496; discussion 1496-1497.
55. Jarnagin WR, Ruo L, Little SA, Klimstra D, D'Angelica M, DeMatteo RP, et al,. (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98: 1689-1700.
56. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y,. (2007) Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg 31: 1256-1263.
57. Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S,. (2001) Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 8: 154-157.
58. Macdonald OK, Crane CH,. (2002) Palliative and postoperative radiotherapy in biliary tract cancer. Surg Oncol Clin N Am 11: 941-954.
59. Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H, et al,. (2000) Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46: 581-587.
60. Pitt HA, Nakeeb A, Abrams RA, Coleman J, Piantadosi S, Yeo CJ, et al,. (1995) Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 221: 788-797; discussion 797-798.
61. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al,. (2002) Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 95: 1685-1695.
62. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al,. (2012) Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 308: 147-156.
63. Horgan AM, Amir E, Walter T, Knox JJ,. (2012) Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 30: 1934-1940.
64. Eckel F, Schmid RM,. (2007) Emerging drugs for biliary cancer. Expert Opin Emerg Drugs 12: 571-589.
65. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al,. (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362: 1273-1281.
66. Hezel AF, Zhu AX,. (2008) Systemic therapy for biliary tract cancers. Oncologist 13: 415-423.
67. Hezel AF, Deshpande V, Zhu AX,. (2010) Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 28: 3531-3540.
68. Jarnagin WR, Klimstra DS, Hezel M, Gonen M, Fong Y, Roggin K, et al,. (2006) Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome. J Clin Oncol 24: 1152-1160.
69. Thomas MB,. (2007) Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. Crit Rev Oncol Hematol 61: 44-51.
70. Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, et al,. (2013) Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 4: 153-162.
71. Lee J, Park SH, Chang HM, Kim JS, Choi HJ, Lee MA, et al,. (2012) Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 13: 181-188.
72. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al,. (2011) Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 117: 1498-1505.
73. Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP,. (2011) Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 66: 322-328.
74. Vogl TJ, Naguib NN, Nour-Eldin NE, Bechstein WO, Zeuzem S, Trojan J, et al,. (2012) Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 131: 733-740.
75. Shen WF, Zhong W, Liu Q, Sui CJ, Huang YQ, Yang JM,. (2011) Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World J Surg 35: 2083-2091.
76. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, et al,. (2012) Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastro Hepatol 24: 437-443.
77. Hoffmann RT, Paprottka PM, Schon A, Bamberg F, Haug A, Durr EM, et al,. (2012) Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 35: 105-116.
78. Saxena A, Bester L, Chua TC, Chu FC, Morris DL,. (2010) Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 17: 484-491.
79. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al,. (2008) Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 113: 2119-2128.
80. Jarnagin WR, Schwartz LH, Gultekin DH, Gonen M, Haviland D, Shia J, et al,. (2009) Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 20: 1589-1595.